Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Walker–Warburg syndrome (WWS) is the most severe form of muscular dystrophy-dystroglycanopathy, type A, characterized by congenital muscular dystrophy with eye and brain malformations. CRPPA (HGNC:37276) encodes isoprenoid synthase domain containing (ISPD), a cytidyltransferase required for α-dystroglycan O-mannosylation. Recessive mutations in CRPPA disrupt the initial step of laminin-binding glycan synthesis, leading to defective dystroglycan processing and the Walker–Warburg phenotype.
Genetic evidence supports autosomal recessive inheritance with compound heterozygous and homozygous variants. To date, 15 probands have been reported in unrelated families with biallelic CRPPA variants, including loss-of-function, splice-site, and missense alleles (e.g., c.614G>T (p.Arg205Leu) in one patient) ([PMID:24120487];[PMID:23288328];[PMID:33199158];[PMID:26087224]).
Segregation analysis in seven families has demonstrated co-segregation of biallelic CRPPA variants with disease, confirming recessive transmission and supporting a definitive gene–disease relationship.
Functional complementation assays in patient fibroblasts showed restoration of dystroglycan O-mannosylation upon wild-type ISPD expression, and in vitro studies established cytidyltransferase activity toward ribitol 5-phosphate. Mass spectrometry mapping of α-dystroglycan glycans further confirmed loss of ribitol phosphate modification in ISPD-deficient cells ([PMID:22522420];[PMID:26687144];[PMID:27601598]).
Clinically, affected individuals present with Type II cobblestone lissencephaly, hydrocephalus, seizures, ocular malformations, and profound psychomotor arrest. Diagnosis is established by genetic testing of CRPPA and other dystroglycanopathy genes in infants with these hallmark features.
Gene–Disease AssociationDefinitive15 probands across unrelated families; multiple pedigrees with homozygous or compound heterozygous segregation and functional rescue assays Genetic EvidenceStrong15 recessive CRPPA variants including loss-of-function and splice-site alleles in 15 probands; segregation in seven families Functional EvidenceStrongFibroblast complementation, enzymatic cytidyltransferase assays, and mass spectrometry mapping confirm loss-of-function mechanism |